Merz Aesthetics® Launches Ultherapy PRIME® in the EMEA Region at the 2025 IMCAS World Congress
23.1.2025 09:00:00 CET | Business Wire | Press release
New Data is presented in the field of regenerative aesthetics
Merz Aesthetics launches Ultherapy PRIME® in Europe, Middle East and Africa, an evolution of the non-invasive skin lifting Ultherapy® and presents six abstracts at the 2025 International Master Course on Aging Science (IMCAS) World Congress highlighting its product portfolio and its contribution to the field of regenerative aesthetics.
“Our new Ultherapy PRIME® device demonstrates our commitment to persist in innovation,” said Gonzalo Mibelli, EMEA President, Merz Aesthetics. “As one of the leaders in non-invasive lifting, we’re excited to bring Ultherapy PRIME to our customers as the next generation, premier platform as a proven technology and customizable, long-lasting* treatment option.”
The focus of this year’s Merz Aesthetics Symposium at IMCAS is Regenerative Aesthetics. “Patients are looking for more sustainable ways to address aging with regenerative aesthetic treatments providing both preventive and restorative methods to improve skin health and enhance long-term confidence,” said Dr. Kerstin Olsson, Head of Medical Affairs EMEA at Merz Aesthetics. “By collaborating with experts in aesthetics and aging science, this year’s Congress enables us to showcase our advancements and leadership in this field.”
Merz Aesthetics organized a program led by notable medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the event.
- Merz Aesthetics Symposium RegenX: Elevating Skin, Lifting Confidence. – Dr. Joyce Lim, Dr. Julia Sevi, Dr. Tatjana Pavicic, Dr. Omar Haroon, Dr. Daria Voropai, Saturday, February 1, 10:30 – 12:30
- Ultherapy PRIME® Golden Lounge:
- Opening with Dr. Sabrina Fabi, Thursday, January 30, 12:30
- Expert Roundtable “Non-invasive Regenerative Biostimulation” – Dr. Tatjana Pavicic, Dr. Kerstin Ortlechner, Dr. Sonja Sattler, Thursday, January 30, 14:30
- Expert Roundtable “Importance of Visualization” – Dr. Julia Sevi, Dr. Daria Voropai, Dr. Kerstin Ortlechner, Friday, January 31, 10:00
- Expert Talk “Truly non-invasive Regenerative Collagen Biostimulation” – Dr. Tatjana Pavicic, Dr. Alec McCarthy, Friday, January 31, 12:45
- IMCAS Product Analysis Session “HA Skinboosters” – Dr. Mimi Borelli, Global Medical Affairs, Merz Aesthetics, Thursday, January 30, 13:30 – 15:00
- IMCAS Economic Tribune Roundtable – Bob Rhatigan, CEO, Merz Aesthetics, Friday, January 31, 16:00 – 18:00
- IMCAS Product Analysis Session “Aesthetic Toxins: Pipeline & Future” – Andy Curry, PhD, Associate Medical Director, Merz Aesthetics, Saturday, February 1, 14:00 ‒ 15:30
Merz Aesthetics Booth Talks
- Connecting with Confidence: Global Insights for a more patient centered approach – Dr. Shannon Humphrey, Thursday, January 30, 14:30
- The power of synergy for challenging cases – Dr. Larisa Pfahl, Thursday, January 30, 15:30
- Standing out in a competitive marketplace: Building an influential brand in Aesthetics – Dr. Audrey Neff, Friday, January 31, 11:00
- 2 is better than 1: Optimizing Results – Dr. Chris Hutton, Friday, January 31, 13:00
- Synergistic strategies for décolleté treatment in mature patients – Dr. Marie-Eugénie Nichanian-Broglia, Friday, January 31, 13:30
- Enhancing Skin Quality: Case study and clinical outcome – Dr. Tatiana Kuznechenkova, Friday, January 31, 15:30
E-Poster Presentations
Virtual posters will be available for viewing on-site throughout the Congress and displayed on the virtual e-poster platform with detailed abstracts.
- CaHA microspheres stimulate proteoglycan expression, supporting improved skin quality and elasticity. Authors: Yoana Dimitrova, MSc; Christian Hartmann, PhD; Kristina Riegel, PhD; Daniela Schäfer, PhD; Christina Wollenburg, PhD; Kay Marquardt, PhD; Thomas Hengl; PhD
- Exploring the mode of action of elastin stimulation by CaHA microspheres. Authors: Christian Hartmann, PhD; Kristina Riegel, PhD; Yoana Dimitrova, MSc; Daniela Schäfer, PhD; Christina Wollenburg, PhD; Kay Marquardt, PhD; Thomas Hengl, PhD
- Global Perspectives on Aesthetic Treatments and Approaches for Skin Quality Improvement: Insights from an Expert Advisory Board. Authors: Martina Kerscher, MD; Kate Goldie, MD; Cyro Hirano, MD; Stephen Lowe, MD; Kavita Mariwalla, MD; Milton Moore, MD; Je Young Park, MD; Dusan Sajic, MD; Sonja Sattler, MD; Julieta Spada, MD; Vasanop Vachiramon, MD; Bianca Viscomi, MD
- Microfocused Ultrasound in Regenerative Aesthetics: A Narrative Review on Mechanisms of Action and Clinical Outcomes. Authors: Vasanop Vachiramon, MD; Tatjana Pavicic, MD; Gabriela Casabona, MD; Jeremy B. Green, MD; Jennifer Levine, MD; Je Young Park, MD; Julieta Spada, MD; Mariana Muniz, MD; John Akers, PharmD; Matthew Jackson, PhD; Alec McCarthy, PhD
- Arterioembolic Characteristics of Hyaluronic Acid and Calcium Hydroxylapatite Fillers within an Artificial Arterial Perfusion Model. Authors: Alec D. McCarthy, PhD; Danny J. Soares, MD; Akash Chandawarkar, MD; Julia Fedorova, MS-I; Yu Zhang, MS-I; Larry Blevins, PA-C; Alexis Bowhay, PA-C; Thomas J. Kean, PhD; David K. Funt, MD
- Extracellular Matrix Response to Diluted Calcium Hydroxylapatite Microspheres and Poly-L-Latic Acid Microparticles. Authors: Gabriela Casabona, MD; Kate Goldie, MD; Niamh Corduff, MD; Alec McCarthy, PhD; Korin Leffler, PhD; Thomas Hengl, PhD; Kristina Riegel, PhD
*results can last up to a year or more, Werschler et al. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;(9)2:27-33, Ulthera Instructions For Use.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2025 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA. ULTHERA, ULTHERAPY and ULTHERAPY PRIME are trademarks and/or registered trademarks of Ulthera Inc. in the EU and/or certain other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123568990/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom